Difference between revisions of "Pheochromocytoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "?Regimen |limit=10000|format=sum}} regimens" to "?Regimen |limit=10000|format=sum}} regimens") |
Warner-admin (talk | contribs) m (Text replacement - "===Regimen #" to "===Variant #") |
||
| Line 56: | Line 56: | ||
Also known as m-[131I]iodobenzylguanidine ([131I]MIBG). | Also known as m-[131I]iodobenzylguanidine ([131I]MIBG). | ||
| − | === | + | ===Variant #1 {{#subobject:f474b2|Variant=1}}=== |
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
!Study | !Study | ||
| Line 76: | Line 76: | ||
'''"Repeat 131I-MIBG treatments were administered on a case-by-case basis in an effort to improve the overall response"''' | '''"Repeat 131I-MIBG treatments were administered on a case-by-case basis in an effort to improve the overall response"''' | ||
| − | === | + | ===Variant #2 {{#subobject:53e027|Variant=1}}=== |
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
!Study | !Study | ||
Revision as of 17:39, 22 March 2018
| Section editor | |
|---|---|
 |
Jeena M. Varghese, MBBS Houston, TX |
3 regimens on this page
5 variants on this page
|
Guidelines
NCCN
All lines of therapy
Cyclophosphamide, Vincristine, Dacarbazine
| back to top |
CVD: Cyclophosphamide, Vincristine, Dacarbazine
Regimen
| Study | Evidence |
|---|---|
| Averbuch et al. 1988 | Pilot, <20 pts |
Chemotherapy
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 IV once on day 1
- Dacarbazine (DTIC) 600 mg/m2 IV once per day on days 1 & 2
21-day cycles
References
- Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988 Aug 15;109(4):267-73. link to original article contains protocol PubMed
131I-Metaiodobenzylguanidine (131I-MIBG)
| back to top |
Also known as m-[131I]iodobenzylguanidine ([131I]MIBG).
Variant #1
| Study | Evidence |
|---|---|
| Rose et al. 2003 | Pilot, <20 pts |
Patients underwent stem cell harvest prior to treatment in case autologous stem cell infusion was needed.
Radiotherapy
- 131I-Metaiodobenzylguanidine (131I-MIBG) 12 to 18 mCi/kg (maximum single dose of 850 mCi) IV over 2 hours once on day 1
Supportive medications
- Intravenous fluids started 12 hours before 131I-MIBG administration.
- Potassium iodide (KI) 6 mg/kg PO once at least 2 hours prior to 131I-MIBG, then potassium iodide (KI) 0.88 mg/kg PO Q4H x 7 days, then potassium iodide (KI) 1 mg/kg PO (frequency not specified) "for 45 days after the infusion."
- Potassium perchlorate 8 mg/kg once at least 2 hours prior to 131I-MIBG, then potassium perchlorate 2 mg/kg PO Q6H x 5 days.
"Repeat 131I-MIBG treatments were administered on a case-by-case basis in an effort to improve the overall response"
Variant #2
| Study | Evidence |
|---|---|
| Krempf et al. 1991 | Pilot, <20 pts |
Radiotherapy
- m-[131I]iodobenzylguanidine ([131I]MIBG) 740 megabequerel/mg every 3 months
References
- Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ, Aubert B, Carpentier P, Fleury-Goyon MC, Gibold C et al. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 1991 Feb;72(2):455-61. link to original article contains protocol PubMed
- Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003 Jul 15;98(2):239-48. link to original article contains verified protocol PubMed